Acute Myeloid Leukemia Market Report

Global Acute Myeloid Leukemia Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 10, 2022
  • PAGES：171
  • REPORT CODE：GMM806431
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Acute Myeloid Leukemia market report explains the definition, types, applications, major countries, and major players of the Acute Myeloid Leukemia market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Sunesis Pharmaceuticals

    • Astellas Pharma

    • Eisai

    • Genzyme Corporation

    • Celgene Corporation

    • CTI Biopharma Corp

    • Cephalon

    • Abbvie

    • Clavis Pharma

    By Type:

    • Chemotherapy

    • Radiation Therapy

    • Stem Cell Transplant

    • Targeted Therapy

    • Others

    By End-User:

    • Hospital

    • Retails Drug Stores

    • Ambulatory Care Centers

    • Oncology Centers

    • Clinics

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Acute Myeloid Leukemia Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Acute Myeloid Leukemia Outlook to 2028- Original Forecasts

    • 2.2 Acute Myeloid Leukemia Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Acute Myeloid Leukemia Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Acute Myeloid Leukemia Market- Recent Developments

    • 6.1 Acute Myeloid Leukemia Market News and Developments

    • 6.2 Acute Myeloid Leukemia Market Deals Landscape

    7 Acute Myeloid Leukemia Raw Materials and Cost Structure Analysis

    • 7.1 Acute Myeloid Leukemia Key Raw Materials

    • 7.2 Acute Myeloid Leukemia Price Trend of Key Raw Materials

    • 7.3 Acute Myeloid Leukemia Key Suppliers of Raw Materials

    • 7.4 Acute Myeloid Leukemia Market Concentration Rate of Raw Materials

    • 7.5 Acute Myeloid Leukemia Cost Structure Analysis

      • 7.5.1 Acute Myeloid Leukemia Raw Materials Analysis

      • 7.5.2 Acute Myeloid Leukemia Labor Cost Analysis

      • 7.5.3 Acute Myeloid Leukemia Manufacturing Expenses Analysis

    8 Global Acute Myeloid Leukemia Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Acute Myeloid Leukemia Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Acute Myeloid Leukemia Export by Region (Top 10 Countries) (2017-2028)

    9 Global Acute Myeloid Leukemia Market Outlook by Types and Applications to 2022

    • 9.1 Global Acute Myeloid Leukemia Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Radiation Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Stem Cell Transplant Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Targeted Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Acute Myeloid Leukemia Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Retails Drug Stores Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ambulatory Care Centers Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Oncology Centers Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Clinics Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Acute Myeloid Leukemia Market Analysis and Outlook till 2022

    • 10.1 Global Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.2.2 Canada Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.2.3 Mexico Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.2 UK Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.3 Spain Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.4 Belgium Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.5 France Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.6 Italy Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.7 Denmark Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.8 Finland Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.9 Norway Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.10 Sweden Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.11 Poland Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.12 Russia Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.3.13 Turkey Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.2 Japan Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.3 India Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.4 South Korea Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.5 Pakistan Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.6 Bangladesh Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.7 Indonesia Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.8 Thailand Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.9 Singapore Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.10 Malaysia Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.11 Philippines Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.4.12 Vietnam Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.2 Colombia Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.3 Chile Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.4 Argentina Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.5 Venezuela Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.6 Peru Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.7 Puerto Rico Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.5.8 Ecuador Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.6.2 Kuwait Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.6.3 Oman Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.6.4 Qatar Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.7.2 South Africa Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.7.3 Egypt Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.7.4 Algeria Acute Myeloid Leukemia Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Acute Myeloid Leukemia Consumption (2017-2022)

      • 10.8.2 New Zealand Acute Myeloid Leukemia Consumption (2017-2022)

    11 Global Acute Myeloid Leukemia Competitive Analysis

    • 11.1 Sunesis Pharmaceuticals

      • 11.1.1 Sunesis Pharmaceuticals Company Details

      • 11.1.2 Sunesis Pharmaceuticals Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Main Business and Markets Served

      • 11.1.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Astellas Pharma

      • 11.2.1 Astellas Pharma Company Details

      • 11.2.2 Astellas Pharma Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Astellas Pharma Acute Myeloid Leukemia Main Business and Markets Served

      • 11.2.4 Astellas Pharma Acute Myeloid Leukemia Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Eisai

      • 11.3.1 Eisai Company Details

      • 11.3.2 Eisai Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Eisai Acute Myeloid Leukemia Main Business and Markets Served

      • 11.3.4 Eisai Acute Myeloid Leukemia Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Genzyme Corporation

      • 11.4.1 Genzyme Corporation Company Details

      • 11.4.2 Genzyme Corporation Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Genzyme Corporation Acute Myeloid Leukemia Main Business and Markets Served

      • 11.4.4 Genzyme Corporation Acute Myeloid Leukemia Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Celgene Corporation

      • 11.5.1 Celgene Corporation Company Details

      • 11.5.2 Celgene Corporation Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Celgene Corporation Acute Myeloid Leukemia Main Business and Markets Served

      • 11.5.4 Celgene Corporation Acute Myeloid Leukemia Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 CTI Biopharma Corp

      • 11.6.1 CTI Biopharma Corp Company Details

      • 11.6.2 CTI Biopharma Corp Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 CTI Biopharma Corp Acute Myeloid Leukemia Main Business and Markets Served

      • 11.6.4 CTI Biopharma Corp Acute Myeloid Leukemia Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Cephalon

      • 11.7.1 Cephalon Company Details

      • 11.7.2 Cephalon Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Cephalon Acute Myeloid Leukemia Main Business and Markets Served

      • 11.7.4 Cephalon Acute Myeloid Leukemia Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Abbvie

      • 11.8.1 Abbvie Company Details

      • 11.8.2 Abbvie Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Abbvie Acute Myeloid Leukemia Main Business and Markets Served

      • 11.8.4 Abbvie Acute Myeloid Leukemia Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Clavis Pharma

      • 11.9.1 Clavis Pharma Company Details

      • 11.9.2 Clavis Pharma Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Clavis Pharma Acute Myeloid Leukemia Main Business and Markets Served

      • 11.9.4 Clavis Pharma Acute Myeloid Leukemia Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Acute Myeloid Leukemia Market Outlook by Types and Applications to 2028

    • 12.1 Global Acute Myeloid Leukemia Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Stem Cell Transplant Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Acute Myeloid Leukemia Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Retails Drug Stores Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Ambulatory Care Centers Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Oncology Centers Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Acute Myeloid Leukemia Market Analysis and Outlook to 2028

    • 13.1 Global Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.2.2 Canada Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.2 UK Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.3 Spain Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.5 France Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.6 Italy Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.8 Finland Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.9 Norway Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.11 Poland Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.12 Russia Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.2 Japan Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.3 India Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.3 Chile Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.6 Peru Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.6.3 Oman Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Acute Myeloid Leukemia Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Acute Myeloid Leukemia Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Acute Myeloid Leukemia

    • Figure of Acute Myeloid Leukemia Picture

    • Table Global Acute Myeloid Leukemia Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Acute Myeloid Leukemia Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Stem Cell Transplant Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Retails Drug Stores Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Care Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Table North America Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure United States Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Canada Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Mexico Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table Europe Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure Germany Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure UK Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Spain Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Belgium Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure France Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Italy Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Denmark Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Finland Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Norway Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Sweden Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Poland Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Russia Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Turkey Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table APAC Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure China Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Japan Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure India Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure South Korea Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Thailand Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Singapore Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Philippines Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table South America Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure Brazil Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Colombia Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Chile Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Argentina Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Peru Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table GCC Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure Bahrain Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Oman Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Qatar Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table Africa Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure Nigeria Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure South Africa Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Egypt Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Algeria Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table Oceania Acute Myeloid Leukemia Consumption by Country (2017-2022)

    • Figure Australia Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Acute Myeloid Leukemia Consumption and Growth Rate (2017-2022)

    • Table Sunesis Pharmaceuticals Company Details

    • Table Sunesis Pharmaceuticals Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sunesis Pharmaceuticals Acute Myeloid Leukemia Main Business and Markets Served

    • Table Sunesis Pharmaceuticals Acute Myeloid Leukemia Product Portfolio

    • Table Astellas Pharma Company Details

    • Table Astellas Pharma Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Acute Myeloid Leukemia Main Business and Markets Served

    • Table Astellas Pharma Acute Myeloid Leukemia Product Portfolio

    • Table Eisai Company Details

    • Table Eisai Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai Acute Myeloid Leukemia Main Business and Markets Served

    • Table Eisai Acute Myeloid Leukemia Product Portfolio

    • Table Genzyme Corporation Company Details

    • Table Genzyme Corporation Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genzyme Corporation Acute Myeloid Leukemia Main Business and Markets Served

    • Table Genzyme Corporation Acute Myeloid Leukemia Product Portfolio

    • Table Celgene Corporation Company Details

    • Table Celgene Corporation Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corporation Acute Myeloid Leukemia Main Business and Markets Served

    • Table Celgene Corporation Acute Myeloid Leukemia Product Portfolio

    • Table CTI Biopharma Corp Company Details

    • Table CTI Biopharma Corp Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table CTI Biopharma Corp Acute Myeloid Leukemia Main Business and Markets Served

    • Table CTI Biopharma Corp Acute Myeloid Leukemia Product Portfolio

    • Table Cephalon Company Details

    • Table Cephalon Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cephalon Acute Myeloid Leukemia Main Business and Markets Served

    • Table Cephalon Acute Myeloid Leukemia Product Portfolio

    • Table Abbvie Company Details

    • Table Abbvie Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbvie Acute Myeloid Leukemia Main Business and Markets Served

    • Table Abbvie Acute Myeloid Leukemia Product Portfolio

    • Table Clavis Pharma Company Details

    • Table Clavis Pharma Acute Myeloid Leukemia Sales, Price, Value and Gross Profit (2017-2022)

    • Table Clavis Pharma Acute Myeloid Leukemia Main Business and Markets Served

    • Table Clavis Pharma Acute Myeloid Leukemia Product Portfolio

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Stem Cell Transplant Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retails Drug Stores Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Care Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Table North America Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure United States Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure Germany Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure China Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure Brazil Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Acute Myeloid Leukemia Consumption Forecast by Country (2022-2028)

    • Figure Australia Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Acute Myeloid Leukemia Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US